Loading
Led CheckMate 067, the trial whose ten-year data showed half of advanced melanoma patients on nivolumab plus ipilimumab are alive.
Jedd Wolchok (Weill Cornell Medicine; formerly MSKCC) was principal investigator of CheckMate 067, which established nivolumab plus ipilimumab as the most durable therapy in advanced melanoma with median survival beyond six years and ten-year melanoma-specific survival near 50%. He led early ipilimumab development, defined the immune-related response criteria, and co-founded the Parker Institute network. His laboratory studies mechanisms of checkpoint blockade.
For patients with advanced melanoma, immunotherapy offers a realistic chance of long-term survival and probably cure, and the ten-year data show that patients who are alive and progression-free at three years rarely die of melanoma afterwards. Nivolumab plus ipilimumab gives the best long-term results but at a high price in serious side effects; nivolumab alone or nivolumab plus relatlimab are alternatives for patients at lower risk or with autoimmune concerns. The trial is also a caution about surrogate endpoints: the survival plateau took years to become visible.
This is the standard overview of checkpoint immunotherapy for clinicians and scientists, tying together the trial results and the biology of response and resistance that guide today's combination trials.
This paper launched the immunotherapy era. It was the first randomised evidence that taking a brake off the immune system could extend life in a solid cancer, and it introduced clinicians to immune-related adverse events and to responses that arrive late or after apparent progression. Ipilimumab alone has since been superseded by PD-1 antibodies and combinations, but every checkpoint programme traces back to this result.
Shares Advanced melanoma (unresectable stage III and stage IV), Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy, trialist.
Shares CheckMate 067, CTLA-4, Advanced melanoma (unresectable stage III and stage IV), Ipilimumab and the tags melanoma, immunotherapy.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tags melanoma, immunotherapy, trialist.
Shares Melanoma and the tags melanoma, immunotherapy, trialist.
Shares Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma, CheckMate 067, CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma, CTLA-4.
Shares CheckMate 067, Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy.
Shares Melanoma and the tags melanoma, immunotherapy, trialist.
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag immunotherapy.